Physician profile
Jimmy Locklear
NPI 1518965979
$2,616.61
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,133 · 2020: $268 · 2021: $193 · 2022: $388 · 2023: $520 · 2024: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $634.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $460.49 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $246.06 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $242.01 | 2019-2023 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals Lp | $195.74 | 2019-2023 | Brilinta, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.63 | 2019-2023 | Jardiance |
| Esperion Therapeutics, INC. | $170.54 | 2021-2024 | Nexletol, Nexlizet |
| Novartis Pharmaceuticals Corporation | $163.64 | 2019-2023 | |
| Boston Scientific Corporation | $148.63 | 2020-2023 | Lux-Dx Insertable Cardiac Monitor |
| Biotronik INC. | $143.21 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $119.00 | 2019-2023 | Lifevest |
| Sanofi-Aventis U.S. LLC | $98.23 | 2019-2023 | |
| Edwards Lifesciences Corporation | $77.30 | 2019-2023 | Sapien 3 Ultra Resilia, Mitris Resilia Mitral Valve |
| Amgen INC. | $59.04 | 2019-2023 | Repatha |
| Amarin Pharma, INC. | $48.68 | 2019-2020 | |
| Medtronic Vascular, INC. | $46.71 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braemar Manufacturing, LLC | $45.40 | 2019 | |
| Cardiva Medical, INC. | $30.12 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $25.42 | 2019 | |
| Celgene Corporation | $24.27 | 2023 | Camzyos |
| Gilead Sciences, INC. | $24.16 | 2019 | |
| Portola Pharmaceuticals, LLC | $22.59 | 2019 | |
| Daiichi Sankyo INC. | $19.41 | 2023 | Injectafer |
| Glaxosmithkline, LLC. | $15.95 | 2019 | |
| Pfizer INC. | $11.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jimmy Locklear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.